Quantum BioPharma Advances Lead MS Treatment toward IND Application
Quantum BioPharma announces milestone in MS treatment development with completion of key studies supporting IND application. Learn more about the company's innovative approach and strategic investments.
This news matters as Quantum BioPharma's progress in developing Lucid-21-302 could lead to a new therapy for multiple sclerosis patients. The completion of key studies signifies a significant step in the drug's clinical development, potentially offering hope to those affected by the disease.
